How are bile‑acid sequestrants (cholestyramine, colestipol, colesevelam) indicated, dosed, monitored, and what are their drug interactions and side‑effects when used for LDL‑C lowering?

Bile Acid Sequestrants for LDL-C Lowering

Bile acid sequestrants (BAS) are effective second-line agents for LDL-C reduction, lowering levels by 15-30% depending on agent and dose, with colesevelam being the preferred agent due to superior tolerability and fewer drug interactions compared to cholestyramine and colestipol. 1

FDA-Approved Indications

BAS are indicated as adjunct to diet and exercise for:

• Primary hyperlipidemia in adults (all three agents) 1, 2
• Heterozygous familial hypercholesterolemia in boys and postmenarchal girls aged 10-17 years who cannot reach LDL-C targets despite adequate diet/lifestyle modification (colesevelam specifically) 2
• Type 2 diabetes for glycemic control (colesevelam only—reduces HbA1c by 0.5%) 1

Critical limitation: Do not use when triglycerides >500 mg/dL or in patients with history of hypertriglyceridemia-induced pancreatitis 1, 2

Dosing and Administration

Colesevelam (Preferred Agent)

• Tablets: 6 tablets (3.75 g) once daily OR 3 tablets twice daily with meals and liquid 1
• Oral suspension: One 3.75-g packet once daily OR one 1.875-g packet twice daily, mixed with 8 oz water/juice/diet soft drink, taken with meals 1

Cholestyramine

• 8-16 g/day orally, divided into 2 doses 1

Colestipol

• 2-16 g/day orally, once daily or divided doses 1

Expected LDL-C Reduction

Monotherapy efficacy 1:

• Colesevelam: 15% reduction (6 tablets daily)
• Cholestyramine: 10.4% vs placebo
• Colestipol: 16.3% (5g), 22.8% (10g), 27.2% (15g)

Combination with statins 1:

• Colesevelam adds 10-16% additional LDL-C reduction when combined with low-to-moderate intensity statins
• BAS generally add 15-30% incremental reduction to statin therapy 3

Monitoring Requirements

Before initiating therapy 1:

• Obtain baseline lipid panel including triglycerides (must be <500 mg/dL)

During therapy 1:

• Monitor triglyceride levels regularly—BAS can increase TG and cause acute pancreatitis
• For patients on warfarin: Monitor INR frequently during initiation, then periodically 1
• For patients on metformin with cholestyramine: Monitor glycemic control (cholestyramine increases metformin exposure) 1
• Discontinue immediately if signs/symptoms of acute pancreatitis occur 1

Contraindications

Absolute contraindications 1, 2:

• Triglycerides >500 mg/dL
• History of hypertriglyceridemia-induced pancreatitis
• Bowel obstruction (colesevelam)
• Complete biliary obstruction (cholestyramine, colestipol)
• History of serious hypersensitivity to the specific agent

Avoid in 1:

• Gastroparesis or other GI motility disorders
• History of major GI surgery with risk for bowel obstruction

Drug Interactions

Critical timing rule: Administer other medications at least 4 hours BEFORE BAS to avoid decreased absorption 1, 2

Specific high-risk interactions requiring 4-hour separation 1:

• Cyclosporine
• Oral contraceptives (ethinyl estradiol/norethindrone)
• Olmesartan
• Phenytoin (despite pharmacokinetic study showing no interaction, maintain 4-hour separation per prescribing information) 4
• Sulfonylureas
• Thyroid replacement therapy
• Warfarin

No clinically significant interactions (can be taken simultaneously with colesevelam) 4:

• Aspirin
• Atenolol
• Enalapril
• Rosiglitazone
• Sitagliptin

Important nuance: Colesevelam has greater bile acid specificity than older agents, resulting in fewer drug interactions compared to cholestyramine and colestipol 5, 6

Adverse Effects

Most common (gastrointestinal) 1:

• Constipation (most frequent)
• Dyspepsia
• Nausea

Agent-specific patterns from real-world data 7:

• Cholestyramine: Oropharyngeal irritation (throat irritation, oropharyngeal discomfort)
• Colestipol: Mechanical risks (dysphagia, choking)
• Colesevelam: Musculoskeletal effects (myalgia, muscle spasms)

Serious but rare 1:

• GI obstruction
• Acute pancreatitis (from TG elevation)
• Vitamin K and fat-soluble vitamin deficiencies

Temporal pattern: Most adverse events occur within the first month; 15-16% persist beyond 6 months 7

Special Precautions

Vitamin supplementation 1, 2:

• BAS may decrease absorption of fat-soluble vitamins (A, D, E, K)
• Patients at high risk: those on warfarin, with malabsorption syndromes
• Give oral vitamins at least 4 hours before BAS

Phenylketonuria warning 1, 2:

• Colesevelam oral suspension contains 33 mg phenylalanine per packet—avoid in PKU patients

Pregnancy/lactation 1:

• Considered safe to use (not systemically absorbed)

Cardiovascular Outcomes Evidence

Only cholestyramine has mortality data 1:

• LRC-CPPT trial: 3,806 men with primary hypercholesterolemia followed 7.4 years
• 19% reduction in definite CHD death and/or nonfatal MI (P<0.05)
• Colesevelam and colestipol lack cardiovascular outcomes trials 1

Clinical Pearls

Why colesevelam is preferred 5, 6, 8:

• Better tolerability (less constipation)
• Fewer drug interactions due to higher bile acid specificity
• Once-daily dosing option
• Additional glucose-lowering benefit (HbA1c reduction 0.5%)
• Can offset hyperglycemic effects of statins and niacin 6

Common pitfalls to avoid:

1. Starting BAS in patients with baseline TG >300 mg/dL (can cause severe hypertriglyceridemia) 3
2. Not separating administration from other medications by 4 hours
3. Using in patients with GI motility disorders
4. Forgetting to supplement fat-soluble vitamins in at-risk patients

Practical considerations 1:

• High pill burden (6 tablets daily for colesevelam)
• Inconvenience of oral suspension preparation
• GI side effects limit adherence
• Cost and prior authorization requirements